Met XL Trio 50 Tablet ER is a combination antihypertensive medication containing Cilnidipine (10 mg), Metoprolol Succinate (50 mg), and Telmisartan (40 mg). This extended-release formulation is designed to provide sustained blood pressure control in patients with hypertension. Cilnidipine, a calcium channel blocker, acts by inhibiting L-type and N-type calcium channels, resulting in vasodilation and reduced peripheral resistance. Metoprolol Succinate, a selective beta-1 adrenergic receptor blocker, decreases heart rate and myocardial contractility, thereby reducing cardiac output and oxygen demand. Telmisartan, an angiotensin II receptor blocker (ARB), prevents vasoconstriction and aldosterone secretion by selectively blocking the AT1 receptor, contributing to further blood pressure reduction. The combination of these three agents targets multiple physiological pathways involved in hypertension, offering enhanced efficacy compared to monotherapy. Met XL Trio 50 Tablet ER is indicated for the management of essential hypertension, particularly in patients requiring multi-drug therapy to achieve optimal blood pressure control. It should be used under medical supervision, with monitoring for potential side effects such as hypotension, bradycardia, dizziness, and electrolyte imbalances. Dose adjustments may be necessary based on patient response and tolerability.